# Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

> **NCT02416388** · PHASE2,PHASE3 · RECRUITING · sponsor: **University Hospital, Angers** · enrollment: 3100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Idarubicin
- **DRUG:** Daunorubicin
- **DRUG:** HD Cytarabine
- **DRUG:** Cyclosporine
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolic acid (MPA)
- **DRUG:** vosaroxin
- **DRUG:** ID cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02416388
- **Lead sponsor:** University Hospital, Angers
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2025-07
- **Final completion:** 2032-01
- **Target enrollment:** 3100 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02416388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02416388, "Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02416388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*